stu wrote:Hi .
Avastin is not coming back any time soon for Colorectal patients ...
"... [The NICE] appraisals are based primarily on evaluations of efficacy and cost-effectiveness in various circumstances..."
"Keytruda will be an expensive treatment option ... Merck has disclosed that its new PD-1 inhibitor will cost payers $12,500 per month or about $150,000 per year.... . Keytruda now looks set to become a blockbuster drug for Merck and a leading drug within the PD-1 inhibitor class..."
stu wrote:I help out at a cancer charity and it pains me to see people running out of treatment options yet when I start to ask about it , all I see is total confusion .
Users browsing this forum: FightCRC, Google [Bot], Yahoo [Bot] and 44 guests